Immunogenicity assessment remains a critical component in the development of both vaccines and biotherapeutics, yet the underlying strategies and regulatory expectations differ significantly between these modalities. This webinar will explore the evolving landscape of immunogenicity bioanalysis, with a focus on the differential approaches required for vaccines versus therapeutic proteins and biologics.
Participants will gain insights into key factors influencing immunogenicity, including product-related attributes, patient-specific variables, and study design considerations. The session will also address common challenges in anti-drug antibody (ADA) detection and characterization, highlighting assay development complexities, sensitivity considerations, and data interpretation nuances.
Through real-world case studies from Aragen Biosafety Solutions, the webinar will illustrate practical solutions to overcome these challenges across both preclinical and clinical settings. Additionally, we will discuss emerging opportunities and the growing market potential for ADA services, driven by the expanding pipeline of biologics and next-generation vaccines.
Key Reasons to Attend
1. Understand Differential Immunogenicity Strategies : Learn key factors influencing immunogenicity for vaccines versus biotherapeutics.
2. Master ADA Detection Challenges : Address common anti-drug antibody detection and characterization complexities.
3. Apply Real-World Solutions: Gain practical insights through Aragen Biosafety Solutions case studies.
4. Explore Market Opportunities: Discuss emerging ADA service opportunities in expanding biologics pipelines.
Key Topics Covered
Immunogenicity Assessment Fundamentals
ADA Detection & Characterization
Case Studies & Market Insights
This session is designed for professionals involved in:
Secure your spot today and learn how integrated DS–DP development accelerates your path to clinic.
